We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.50
Bid: 29.00
Ask: 32.00
Change: 0.50 (1.67%)
Spread: 3.00 (10.345%)
Open: 30.50
High: 31.00
Low: 29.50
Prev. Close: 30.00
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

9 Jan 2018 07:00

RNS Number : 2817B
Ilika plc
09 January 2018
 

 

Ilika plc

('Ilika,' the 'Company,' or the 'Group')

 

Half-year Report

 

Ilika (AIM: IKA), a pioneer in solid-state battery technology and materials innovation, announces its unaudited half yearly report for the six months ended 31 October 2017.

 

Operational Highlights

· Exchanged detailed Stereax® performance data with over 60 potential OEM partners

· Shipped sample batteries to 10 potential OEM partners for detailed technical evaluation

· Three of these have progressed to development and deployment partnerships:

o Advanced a development programme to integrate a Stereax® battery in a miniature medical implant product (value to Ilika of £700,000 over 18 months from March 2017)

o Commenced a development programme to integrate a Stereax® battery with a photovoltaic energy harvesting solution from Lightricity (ex-Sharp) (value to Ilika of £320,000 over two years from July 2017)

o Secured a deployment programme with Titan Wind Energy, China's largest wind turbine manufacturer, to use Stereax® M250 batteries to power strain sensors for turbine blade condition monitoring (value to Ilika of £400,000 over two years from March 2018)

· Continued to implement the Stereax® roadmap to achieve increased capacity per footprint and miniaturisation requirements

· Executed the following materials development programmes:

o plasmonic lenses and Heat Assisted Magnetic Recording (HAMR) materials with Seagate

o battery materials with Johnson Matthey

o game changing energy materials with Toyota and 

o aerospace alloys in collaboration with partners including Rolls Royce, GKN and BAE Systems.

· Expanded proprietary IP with patents granted in USA for core-shell catalysts for fuel cells

· ISO 9001Certification achieved in December 2017

 

Financial Summary

· Total revenue for the period £1.0m (H1 2016: £0.3m)

· Loss per share 2p (H1 2016: 3p per share)

· Cash balance at period end £3.9m (H1 2016: £7.1m)

 

Commenting on the results Graeme Purdy, CEO of Ilika, said: "In the first half of the year Ilika has delivered a series of Stereax® development and deployment partnerships which are driving revenue growth and enhancing insight into the addressable sectors for its technology. The progress being made towards the commercialisation of Stereax technology is illustrated by the increased number of Stereax® samples sent to a diverse range of potential OEM partners for evaluation. Ilika is well-positioned to generate value from its globally-recognised reputation for expertise in solid-state materials and battery technology and is seeing increased corporate interest consistent with greater activity in the global battery sector.

 

Ilika plc

Graeme Purdy, Chief Executive

Steve Boydell, Finance Director

+44 (0)23 8011 1400

 

 

 

 

NUMIS Securities Limited

Paul Gillam/Oliver Cardigan/James Black

+44 (0) 20 7260 1000

 

 

 

Walbrook PR Ltd

+44 (0)20 7933 8780 or ilika@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893

Paul Cornelius

Mob: +44 (0)7827 879 460

Lianne Cawthorne

Mob: +44 (0)7584 391 303

 

Joint Chairman's and CEO's Statement

Review of Period

 

Ilika has continued to pursue its strategy of developing and commercialising its proprietary solid-state batteries, underpinned by its technology platform for the high throughput development of materials for the energy, electronics and aerospace sectors.

 

Stereax® solid-state battery technology

Ilika has been active in the development of solid-state battery technology since 2008, when it commenced a collaboration with Toyota, principally to develop materials suitable for use in batteries for hybrid vehicles. During that collaboration, Ilika and Toyota filed joint patent applications protecting relevant materials and processes for the development and manufacture of solid-state batteries. The key advantages of solid-state batteries relative to standard lithium-ion batteries are:

· Non-flammable

· 6 x faster charging

· 4x longer charge retention

· 2x increased energy density, making them half the volume for a given electrical charge

· 1/10th the leakage current.

 

Ilika identified that these benefits make solid-state batteries particularly suitable for powering wireless sensors, which are the end-nodes for the "Internet of Things" (IoT). While analysts' estimates vary, we believe there are about 15 billion sensors already deployed, with the majority of these sensors hard-wired either to the grid, or to larger batteries, for example those used to power consumer electronics devices. Sensors can also be powered by primary (disposable) batteries. The number of sensors being deployed is growing rapidly and many of the important use-cases involve sensors in environments where it is expensive or inconvenient to connect them with cables. Also, in the trillion-sensor scenario, where sensors become ubiquitous, we understand the use of disposable coin cells becomes unsustainable. Ilika's solution is to combine its rechargeable Stereax® technology with miniature energy harvesters such as small photovoltaic panels (that convert light to electricity), thermoelectric devices (that convert heat to electricity) and piezoelectric devices (that convert movement to electricity).

 

Ilika's Stereax® battery technology is differentiated from other solid-state batteries through its choice of materials and its use of an efficient evaporation process that is capable of higher deposition rates than other solid-state routes. This results in the following benefits relative to previous solid-state battery designs:

· Ability to stack cells in a continuous process prior to encapsulation, increasing the energy capacity per footprint of battery

· Less encapsulation required

· High temperature resilience

 

Within the IoT market, there are many segments which are addressable with Ilika's technology. The unique benefits of Stereax® batteries make them particularly useful for medical implants and industrial IoT applications. Miniature Stereax® batteries can enable medical devices in a way that is currently not possible with conventional lithium-ion batteries. Their compact, high energy density, high power characteristics make them useful for a range of medical implant applications covering blood pressure monitoring to neuro-stimulation. Industrial IoT, or Industry 4.0 as it is sometimes referred to, requires batteries that can reliably operate at elevated temperatures above those for which standard lithium-ion batteries are rated.

 

In discussion with its potential partners, Ilika has defined a development roadmap for its Stereax® batteries. The Stereax® M250 product was launched in 2016 and in 2017 this was followed up with the launch of the P180, designed for use in hostile environments. Further Stereax® product launches are expected in 2018. Ilika has entered into in excess of 60 application discussions with potential OEM partners around the world. In addition, Ilika has sent samples of batteries to 10 potential partners for their detailed evaluation and validation. Three of these discussions have now progressed to development and deployment partnerships, which are discussed in the commercial section below.

 

The Stereax products that Ilika is marketing to its partners are defined by a licensing package including the following:

· Battery architecture design

· Detailed definition of the materials composition and properties

· Manufacturing process description

· Sample battery devices

· IP portfolio

 

Over the past few months Ilika has been approached by a number of significant commercial partners interested in collaborating with Ilika to expand its product development roadmap to include larger capacity batteries suitable for use in consumer electronics, domestic storage of energy and electric powered vehicles. In order to address these applications, Ilika is developing manufacturing processes suitable for forming battery materials in quantities which facilitate energy storage on a scale several orders of magnitude larger than that achievable using current vacuum deposition methods. The Stereax roadmap is now showing this technical innovation, which has the code-name "Goliath". Further information will be forthcoming on this development path in future updates.

 

Commercial Progress

Ilika's intention is to license its technology to OEM partners using the model that has become standard in the semiconductor industry, based on license fees and royalties. Using its pilot line, Ilika has produced samples of its M250 and P180 batteries, which it has used to provide initial quantities of product to seed the market for OEM's. Licensing may also involve the use of 3rd party foundries working under contract to OEM's.

 

Ilika has continued to pursue a three-phase strategy for the commercialisation of its battery technology:

· Optimisation of the battery architecture for specific applications

· Validation and integration of the batteries into application systems

· Technology transfer and licensing for manufacture

 

The development of the published Stereax roadmap is demonstration of the implementation of the first phase of this strategy. The second phase commenced in 2017, as demonstrated by the three development and deployment programmes announced in the course of the year:

1. The optimisation of Stereax technology for miniature medical implants announced in March 2017 which is a £700k development programme.

2. Integration of Stereax with photovoltaic harvesters for transport applications in a two-year programme with Lightricity (ex-Sharp), which started in July 2017.

3. Deployment of Stereax in sensors to measure strain for condition monitoring in wind turbine blades. This programme will start in March 2018 and is a collaboration with Titan Wind Energy, China's largest wind turbine manufacturer.

 

These three programmes can be seen as lead indicators of the areas into which Stereax technology will be licensed as part of the third phase of commercialisation.

 

Materials Development Portfolio

Ilika continues to support an active portfolio of materials development projects, which are carried out in collaboration with OEM partners. These programmes are a usually done on a shared-IP basis. The project fees make a significant contribution towards covering Ilika's overheads.

 

Energy materials

In February 2017 Ilika commenced the latest in a series of projects with the Toyota Group. This latest project is being carried out with the Toyota Research Institute and its partners in the USA. The project involves the use of materials modelling, machine learning and Ilika's automated materials synthesis and testing techniques.

 

In August 2016, Ilika announced that it is taking part in a three-year project to develop protected anodes for lithium sulphur batteries. Led by Johnson Matthey and including Williams Grand Prix Engineering Ltd, the University of Oxford and the University of Warwick. The aim of the project is to discover new electrolyte composition options which will provide enhanced performance 'pouch cells' that can be made with existing cell fabrication methods. The pouch cells being developed in this project are for large scale renewable energy storage applications that require high capacity and low-cost batteries.

 

Electronic materials

In February 2017 Ilika announced a second project with Seagate to develop photonic materials and processes for hard drives. This follows on from the two-year project with Seagate and the University of Southampton, which commenced in February 2016, with the aim of providing a demonstration of 2D materials for Hard Disk Drive applications. Materials with superior nanophotonic properties are being developed to achieve improved hard drive performance and reliability.

 

Aerospace Alloys

Ilika has continued in its role of leading two aerospace alloy programmes. The first is focussing on superalloy compositions for gas turbine engines with better thermal efficiency than current alloys. The alloys are designed to increase gas turbine performance, reducing CO2 emissions and noise levels at take-off. This is a collaboration with the University of Cambridge, Diamond Light Source and Rolls Royce.

 

The second project is the development of self-healing alloys in collaboration with Reliance Precision Engineering, University of Sheffield, GKN and BAE Systems. This project aims to develop alloys suitable for additive manufacturing processes and to develop a metallic manufacturing process that takes advantage of the flexibility of additive manufacturing and the precision of subtractive manufacturing.

 

Outlook

In the second half of the current financial year Ilika expects to continue to deliver strong revenue growth relative to the previous year. Ilika is focussed on the scale up of its Stereax technology. An important milestone in this process has been the award of ISO 9001 certification to the Company.

 

In addition, Ilika's pipeline of potential OEM partners, who are actively evaluating Stereax batteries, demonstrates that the Company is drawing ever closer to licensing this technology. Ilika is well-positioned to exploit the global trend towards solid-state battery technology and is one of the few global players with an established technology position in this field. Underpinning this is Ilika's foundation of high throughput materials innovation, which continues to attract OEM collaboration partners and support revenue growth.

 

 

Graeme Purdy, CEO

Mike Inglis, Chairman

Ilika plc

 

 

 

 

Consolidated statement of comprehensive income for the six months ended 31 October 2017

 

 

 

Unaudited

 Six months ended

31 Oct 2017

Unaudited

 Six months ended

31 Oct 2016

Audited

Year

ended

30 Apr 2017

 

Notes

£

£

£

 

 

 

 

 

Turnover

 

1,004,112 

328,639 

1,050,667 

Revenue

 

413,572 

54,807 

311,946 

UK grants

 

590,540 

273,832 

738,721 

 

 

 

 

 

Cost of sales

 

(531,024)

(220,101)

(574,272)

 

 

 

 

 

Gross profit

 

473,088 

108,538 

476,395 

Administrative expenses

 

 

 

 

Administrative expenses

 

(1,897,903)

(2,030,138)

(3,863,411)

Share-based payment charge

 

(269,627)

(278,326)

(547,347)

 

 

2,167,530 

2,308,464 

4,410,758 

 

 

 

 

 

Operating loss

 

(1,694,442)

(2,199,926)

(3,934,363)

 

 

 

 

 

Financial income

 

8,654 

5,822 

23,844 

 

 

 

 

 

 

 

 

 

 

Loss before tax

 

(1,685,788)

(2,194,104)

(3,910,519)

Taxation

 

198,308 

217,268 

370,274

 

 

 

 

 

Loss for period/total comprehensive income attributable to owners of parent

 

 

(1,487,480)

 

(1,976,836)

 

(3,540,245)

 

 

 

 

 

Loss per share

 

 

 

 

Basic and diluted

2

(0.02)

(0.03)

(0.05)

 

The results from the periods shown above are derived entirely from continuing operations.

 

Consolidated balance sheet as at 31 October 2017

 

 

 

Unaudited

Six months ended

31 Oct 2017

Unaudited

Six months ended

31 Oct 2016

Audited

Year

ended

30 Apr 2017

 

Notes

£

£

£

ASSETS

 

 

 

 

Non-current assets

 

 

 

 

Intangible assets

 

2,980 

9,088 

2,581 

Property, plant and equipment

 

543,653 

405,573 

451,560 

 

 

 

 

 

Total non-current assets

 

546,633 

414,661 

454,141 

 

 

 

 

 

Current assets

 

 

 

 

Trade and other receivables

 

1,015,866 

674,539 

1,116,367 

Current tax receivable

 

528,309 

240,274 

330,000 

Other financial assets - bank deposits

 

3,268,648 

1,406,305 

2,900,000 

Cash and cash equivalents

 

601,499 

5,665,033 

2,510,884 

 

 

 

 

 

Total current assets

 

5,414,322 

7,986,151 

6,857,251 

 

 

 

 

 

Total assets

 

5,960,955 

8,400,812 

7,311,392 

 

 

 

 

 

 

 

 

 

 

Issued capital and reserves attributable to owners of parent

 

 

 

Issued share capital

 

789,911 

789,911 

789,911 

Share premium

 

23,179,756 

23,179,756 

23,179,756 

Capital restructuring reserve

 

6,486,077 

6,486,077 

6,486,077 

Retained earnings

 

(25,424,258)

(22,912,018)

(24,206,405)

 

 

 

 

 

Total equity

 

5,031,486 

7,543,726 

6,249,339 

 

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

Current liabilities

 

 

 

 

Trade and other payables

 

779,469 

707,086 

912,053 

Provisions

 

150,000 

150,000 

150,000 

 

 

 

 

 

Total liabilities

 

929,469 

857,086 

1,062,053 

 

 

 

 

 

Total equity and liabilities

 

5,960,955 

8,400,812 

7,311,392 

 

 

 

 

 

 

Consolidated cash flow statement for the six months ended 31 October 2017

 

 

Unaudited

Six months ended

31 Oct 2017

Unaudited

Six months ended

31 Oct 2016

Audited

Year

ended

30 Apr 2017

 

£

£

£

Cash flows from operating activities

 

 

 

Loss before taxation

(1,685,788)

(2,194,104)

(3,910,519)

Adjustments for:

 

 

 

Amortisation

2,755 

6,507 

13,014 

Depreciation

99,798 

99,926 

192,331 

Equity settled share based payments

269,627 

278,326 

547,347 

Profit on disposal of plant, property and equipment

(30,129)

(30,783)

Net financial income

(8,654)

(5,822)

(23,844)

Operating cash flow before changes in working capital, interest and taxes

(1,322,262)

(1,845,296)

(3,212,454)

Decrease/(increase) in trade and other

receivables

 

100,501 

 

(119,850)

 

(598,672)

Increase /(decrease) in trade and other payables

(132,584)

(41,043)

163,925 

Cash utilised by operations

(1,354,345)

(2,006,189)

(3,647,201)

Tax received

315,000 

415,274 

Net cash flow from operating activities

(1,354,345)

(1,691,189)

(3,231,927)

 

 

 

 

Cash flows from investing activities

 

 

 

Interest received

8,653 

5,822 

23,844 

Sale of property plant and equipment

30,129 

40,129 

Purchase of intangible assets

(3,154)

Purchase of property, plant and equipment

(191,891)

(106,175)

(253,913)

Increase in other financial assets

(368,648)

(1,406,305)

(2,900,000)

Net cash used in investing activities

(555,040)

(1,476,529)

(3,089,940)

 

 

 

 

Cash flows from financing activities

 

 

 

Proceeds from issuance of ordinary share capital

6,300,000 

6,300,000 

Cost of share issue

(464,661)

(464,661)

Net cash from financing activities

5,835,339 

5,835,339 

 

 

 

 

Net (decrease)/ increase in cash and cash equivalents

(1,909,385)

2,667,621 

(486,528)

 

 

 

 

Cash and cash equivalents at the start of the period

2,510,884 

2,997,412 

2,997,412 

 

 

 

 

Cash and cash equivalents at the end of the period

601,499 

5,665,033 

2,510,884 

 

 

Consolidated statement of changes in equity (unaudited)

 

 

 

 

Share capital

Share premium account

Capital

restructuring reserve

 

Retained earnings

 

 

Total

 

£

£

£

£

£

As at 30 April 2016

663,911

17,470,417 

6,486,077

(21,213,507)

3,406,898 

Issue of shares

126,000

6,174,000 

-

6,300,000 

Expenses of share issue

-

(464,661)

-

(464,661)

Share-based payment

-

278,326 

278,326 

Loss and total

comprehensive income

 

-

 

 

 

(1,976,836)

 

(1,976,836)

As at 31 October 2016

789,911

23,179,756

6,486,077

(22,912,017)

7,543,727 

Share-based payment

-

269,021 

269,021 

Loss and total

comprehensive income

 

-

 

 

 

(1,563,409)

 

(1,563,409)

As at 30 April 2017

789,911

23,179,756

6,486,077

(24,206,405)

6,249,339 

Share-based payment

-

269,627 

269,627 

Loss and total

comprehensive income

 

-

 

 

 

(1,487,480)

 

(1,487,480)

As at 31 October 2017

789,911

23,179,756

6,486,077

(25,424,258)

5,031,486 

 

Share capital

The share capital represents the nominal value of the equity shares in issue.

 

Share premium account

When shares are issued, any premium paid above the nominal value is credited to the share premium reserve.

 

Retained earnings

The retained earnings reserve records the accumulated profits and losses of the Group since inception of the business.

 

Capital restructuring reserve

The capital restructuring reserve arises on the accounting for the share for share exchange. It represents the difference between the value of the issued equity instruments of Ilika Technologies Limited immediately before the share for share exchange and the equity instruments of Ilika plc along with the shares issued to effect the share for share exchange.

 Notes to the consolidated financial statements

 

1. Accounting policies

 

Basis of preparation

 

The interim financial statements, which are unaudited, have been prepared on the basis of accounting policies consistent with International Financial Reporting Standards ("IFRSs") adopted by the European Union. The accounting policies are the same as applied in the Group's latest financial statements.

 

The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all the disclosures in IAS 34 'Interim Financial Reporting'. Accordingly, whilst the interim financial statements have been prepared in accordance with IFRS they cannot be construed as being in full compliance with IFRS.

 

The financial information for the year ended 30 April 2017 does not constitute the full statutory accounts for that period. The Annual Report and Accounts for 30 April 2017 have been filed with the Registrar of Companies. The Independent Auditors' Report on the Annual Report and Accounts for 2017 was unqualified and did not include references to any matters which the auditors drew attention by way of emphasis without qualifying their report and did not contain statements under Section 498(2) or 498(3) of the Companies Act 2006.

 

Going concern

 

The financial statements are prepared on a going concern basis which the directors believe continues to be appropriate. The Group meets its day to day working capital requirements through existing cash resources which, at 31 October 2017, amounted to £3.9m. The directors have prepared projected cash flow information for the period ending twelve months from the date of their approval of these financial statements. On the basis of this cash flow information the directors believe that the Group will be able to continue to trade for the foreseeable future.

 

 

2. Loss per share

 

Loss per ordinary share have been calculated using the weighted average number of shares in issue during the relevant financial periods. The weighted average number of equity shares in issue and the earnings, being loss after tax, are as follows:

 

 

Unaudited

Six months ended

31 Oct 2017

 

Unaudited

Six months ended

31 Oct 2016

 

Audited

Year

ended

30 Apr 2016

 

Number

Number

Number

 

 

 

 

Weighted average number of equity shares

78,991,110 

67,144,371 

73,122,617

 

 

 

 

 

£

£

£

 

 

 

 

Loss, being loss after tax

(1,487,480)

(1,976,836)

(3,540,245)

 

 

 

 

 

The loss attributable to ordinary shareholders and weighted average number of ordinary shares for the purpose of calculating the diluted earnings per ordinary share are identical to those used for basic earnings per share. This is because the exercise of share options and warrants would have the effect of reducing the loss per ordinary share and is therefore not dilutive under the terms of IAS 33.

 

 

 

 

 

- Ends -

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR DVLFBVFFXBBE
Date   Source Headline
26th Apr 20247:00 amRNSAgratas joins Goliath industrialisation programme
23rd Apr 20247:00 amRNSCapital Markets Day and Trading Update
27th Mar 20247:00 amRNSNotice of Capital Markets Day and Investor Q&A
23rd Jan 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNS2024 Conference Schedule
14th Dec 20231:46 pmRNSAward of Share Options, Exercise of Options & TVR
13th Dec 20231:43 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSLithium-ion parity development milestone
24th Nov 20237:00 amRNSTrading Update, Notice of Results & Presentations
20th Nov 20237:00 amRNSKey Technology Development Milestone
9th Oct 20237:00 amRNSAward of Scale-up Grant Funding for Goliath
20th Sep 20233:20 pmRNSResult of AGM & Award of Executive Share Options
18th Aug 20237:00 amRNSPosting of Annual Report and Notice of AGM
4th Aug 20237:00 amRNSSigned agreement with Cirtec Medical
13th Jul 20237:00 amRNSFinal Results
16th Jun 20237:00 amRNSSenior appointment&conversion of preference shares
22nd May 20237:00 amRNSTrading Update & Notice of Results
11th May 20237:00 amRNSFirst Customer Shipments of Stereax M300 Batteries
26th Apr 20237:00 amRNSExercise of Options and Total Voting Rights
11th Apr 20237:00 amRNSFirst Customer Shipment of Stereax® Batteries
8th Mar 20234:35 pmRNSPrice Monitoring Extension
1st Mar 20237:00 amRNSAward of Share Options
31st Jan 202310:30 amRNSDirector/PDMR Shareholding
30th Jan 20232:05 pmRNSSecond Price Monitoring Extn
30th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSAward of Grant Funding for Goliath
19th Jan 20237:00 amRNSHalf-year Report
16th Jan 20237:00 amRNSMOU signed with Cirtec Medical
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20224:40 pmRNSSecond Price Monitoring Extn
28th Dec 20224:35 pmRNSPrice Monitoring Extension
28th Dec 20222:05 pmRNSSecond Price Monitoring Extn
28th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination
17th Nov 20224:40 pmRNSSecond Price Monitoring Extn
17th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.